Clinical Trials Search at Vanderbilt-Ingram Cancer Center
AssesSing a Biomarker PlatfOrm for STratifying IndeterminaTe Pulmonary Nodules; The SPOT IT Platform Trial
Lung
Lung
Lung
N/A
Maldonado, Fabien
NCT06638398
VICC-IDTHO24059
An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors
Multiple Cancer Types
Breast,
Head/Neck,
Lung,
Non Small Cell,
Ovarian,
Phase I,
Uterine
I/II
Eng, Cathy
NCT06526819
VICC-DTPHI23348
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Not Available
II
Esbenshade, Adam
NCT06368817
COGACNS2321
A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Not Available
III
Davis, Elizabeth
NCT06422806
VICC-NTSAR24139
A Phase II Neoadjuvant Clinical Trial of the Androgen Receptor Inhibitor Darolutamide in Early-Stage Androgen Receptor Positive (AR+) Triple-Negative Breast Cancer
Breast
Breast
Breast
II
Abramson, Vandana
NCT07016399
VICC-VCBRE23490
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Not Available
II
Baljevic, Muhamed
NCT06297226
VICC-DTCTT23527
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Hematologic
Hematologic
Hematologic
III
Mohan, Sanjay
NCT06479135
VICC-DTHEM24136
High-Resolution Specimen PET-CT Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Study
Miscellaneous
Miscellaneous
Miscellaneous
I
Topf, Michael
VICCHNP24616
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Multiple Cancer Types
Head/Neck,
Phase I
I
Rosenthal, Eben
VICCHNP24602
A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors
Multiple Cancer Types
The purpose of this study is to evaluate the safety and tolerability of AB521 when taken
alone in participants with advanced solid tumor malignancies and clear cell renal cell
carcinoma (ccRCC).
alone in participants with advanced solid tumor malignancies and clear cell renal cell
carcinoma (ccRCC).
Kidney (Renal Cell),
Phase I
I
Rini, Brian
NCT05536141
VICC-DTURO23168P